English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Few reports discuss the optimal management of patients diagnosed with tuberculosis ( TB ) before scheduled stem cell transplantation ( SCT ), who then proceed with transplantation.    Methods  We found 13 patients with  TB  before  SCT  (proven,  n  = 9; probable,  n  = 3; possible,  n  = 1) in the medical records of our institution.    Results  Most of the patients had pulmonary  TB  ( n  = 8; disseminated,  n  = 2; extrapulmonary,  n  = 3). Eight of 9 patients with proven disease had  SCT  after at least 100 days of anti‐tuberculous medication, ranging from 103 to 450 days. None of those patients suffered  TB ‐related events after  SCT . However, 1 patient with proven pulmonary  TB  who underwent  SCT  after only 40 days of anti‐tuberculous therapy subsequently died of  TB  meningitis. Patients with possible and probable disease had their transplants after 6–176 days of anti‐tuberculous medication, and all were alive at the time of analysis. The entire duration of anti‐tuberculous medication was 12 months in most cases. With a follow‐up duration ranging from 0.7 to 87.5 months, 4 patients died, but  TB  was the cause of death in only 1 case.    Conclusion  In conclusion, for proven cases of  TB ,  SCT  after >100 days of anti‐tuberculous medication is probably feasible and safe, in terms of  TB  control, in patients with various hematologic diseases.

Tuberculosis before hematopoietic stem cell transplantation in patients with hematologic diseases: report of a single‐center experience